The aberrant expression of interleukin-17 (IL-17) has been reported in primary Sj€ ogren's syndrome (pSS). Abnormalities in IL-17 can promote the production of pro-inflammatory cytokines and aggravate autoimmune disorders. The aim of this study was to investigate alterations of IL-17 in patients with pSS and explore the correlation between IL-17 and disease severity. Eight databases were searched for original studies reporting the expression of IL-17 in patients with pSS and controls. Eligible reports were included in the pooled analysis, and subgroup evaluations were performed according to different types of controls and IL-17 measurement methods. Newcastle-Ottawa Scale criteria were used to assess the risk of bias of the included studies. In total, 45 articles are included in the metaanalysis. The expression of IL-17 is significantly increased in patients with pSS compared to controls. Furthermore, patients with pSS without immunosuppressive treatment show markedly higher IL-17 levels. In addition, patients with pSS with positive rheumatoid factors tend to express a higher level of IL-17 than patients with negative rheumatoid factors. Negative correlations between IL-17 levels and ocular parameters are also found in patients with pSS. The results are similar after adjustment by "trim and fill" methods. In conclusion, the expression of IL-17 is obviously increased in patients with pSS, especially among those without immunosuppressive treatment. In addition, IL-17 level correlates with the disease severity of pSS. These findings demonstrate the significance of IL-17 overexpression in patients with pSS and may provide insights for the development of therapeutic interventions targeting IL-17 for pSS.
| INTRODUCTION
Sj€ ogren's syndrome (SS) is a chronic autoimmune disease in which the exocrine glands are the main tissue damaged, especially salivary and lacrimal glands. As one of most common autoimmune diseases, SS affects 0.5% to 1.0% of the population and is most commonly observed in women in the fifth decade of life.
1 SS can present as primary Sj€ ogren's syndrome (pSS) or secondary Sj€ ogren's syndrome (sSS) according to whether the patient has another autoimmune disease. 2 Clinically, dryness is the overwhelming complaint, although other general features (fatigue and chronic pain) and extraglandular manifestations (including lymphoma) are also involved. 3, 4 The diagnostic criteria set by the American-European Consensus Group (AECG), American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) all highlight the significance of the ocular, oral and histopathological symptoms, as well as autoantibodies, in the classification of pSS. 5, 6 Unfortunately, no curative agents exist for SS.
and adaptive immune responses has been proven beyond doubt. The adaptive immune system is activated pathogenically by signals arising from the aberrant innate immune response, resulting in B and T cell abnormalities in salivary gland lesions and the peripheral blood of SS mouse models and patients. 11, 12 The ensuing abnormal inflammatory cytokines and autoantibodies could invade the salivary glands, as well as other target organs, contributing to the incidence and development of SS. 12 Among the aberrant cytokines, interleukin-17 (IL-17) is an important proinflammatory cytokine that is mainly secreted by Th17 cells. Under normal conditions, IL-17 plays a potent role in immunity against extracellular bacteria and fungi, by activating or recruiting cytokines and chemokines. 13, 14 However, IL-17 is not always beneficial for host defence. IL-17 is involved in the pathogenesis of multiple autoimmune diseases, including systemic lupus erythematosus, psoriasis, inflammatory bowel diseases and rheumatoid arthritis. 13 It has also been reported that IL-17 could induce cytokines and chemokines to promote lymphocyte recruitment, activation and migration to target tissues. 15 Furthermore, IL-17 could potentiate aberrant autoimmune responses by favouring B and T cell survival and protecting T cells from apoptosis. 16 As the first studies showed that IL-17 was present in salivary gland lesions from patients with pSS, 17, 18 the pathologic role of IL-17 in SS has attracted ever greater attention. In patients with pSS, an increase in IL-17 has been found in both the serum and the affected glandular lesions, indicating that IL-17 may play a key role in the development of both the glandular and systemic manifestations of the disorder. 19, 20 Genetically, IL-17 À/À mice were completely resistant to SS induction, showing no evidence of disease symptoms or histopathological changes in salivary glands. In contrast, transfer of Th17 cells rapidly induced the onset of SS-like sialadenitis in immunized IL-17 À/À mice. 21 In addition, the single nucleotide polymorphism rs4711998 in IL-17 has been reported to be associated with a germinal centre-like structure in salivary glands, which is a possible predictor of later lymphoma development in patients with pSS. 22 These results further suggest that IL-17 plays a pathogenic role in the induction of glandular damage, as well as in the poor prognosis of patients with pSS. Even though many studies have reported the expression of IL-17 in patients with pSS, no comprehensive and systematic study has summarized the alterations of IL-17 expression in patients with pSS. Meanwhile, the connection between IL-17 and SS symptoms has not been clearly elucidated. Thus, we perform the systematic review and metaanalysis to evaluate alterations of IL-17 in patients with pSS and their significance to disease severity.
| MATERIALS AND METHODS

| Search strategy
This review was performed in accordance with the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement. 23 We searched PubMed, Embase, Web of Science, Ovid, Cochrane Database, Wanfang Data, CNKI and VIP Information databases for original articles published up to 1 December 2017, using the keywords "Sj€ ogren's Syndrome" OR "Sj€ ogrens Syndrome" OR "Sj€ ogren Syndrome" OR "Sicca Syndrome" AND "interleukin-17" OR "IL-17", without any limitations. The authors of meeting abstracts that met the inclusion criteria were contacted for original data (no additional data were provided). Complementary manual searching was performed using the reference lists of relevant original or review articles. The searches were conducted by 2 independent investigators (L Zhang and P Zhou). Any discrepancies were resolved by discussion or by input from the third reviewer (H Hua). The controls involved in the meta-analysis were divided into 2 types. The first control type was non-sicca control, which included individuals without sicca symptoms. Most individuals in this group were healthy, but some patients with mild topical oral lesions, such as chronic gingivitis and mucoceles, were also included. The second control type was non-SS control, which included patients displaying subjective complaints of dry mouth or eyes, but who did not have SS. The cause of sicca in non-SS controls could be attributed to certain non-autoimmune factors, including non-specific chronic sialoadenitis, head and neck radiation therapy, use of certain medications and disorders of the nervous system. 24 There was no overlap between the 2 control groups.
| Study selection
Inclusion criteria were as follows: (i) original human studies reporting the expression of IL-17 or IL-17-producing T cells in the serum, tears, saliva or salivary glands of patients with pSS; (ii) patients with SS met standard diagnostic criteria, such as ACR and AECG criteria for pSS; (iii) mean and standard deviation (SD) of IL-17 expression were available or could be calculated from the original data; and (iv) a non-sicca control or non-SS control group was essential in the meta-analysis to evaluate the expression of IL-17 in patients with pSS. We set no limitations on age, sex or disease duration, with or without clinical treatment for patients with pSS. Exclusion criteria were as follows: (i) SS cases and controls suffered from other systemic autoimmune diseases; and (ii) studies conducted in animal models or cell lines.
| Data extraction and quality assessment
For statistical analysis, the following items were extracted: authors, country of origin, number of cases, SS diagnostic criteria, age, disease duration, medical treatment history of patients with pSS, mean and SD of IL-17 expression, clinical, serological and histological parameters, including the salivary flow rate, anti-Sj€ ogren's syndrome-related antigen A (Ro/SSA) and anti-Sj€ ogren's syndrome-related antigen B (La/SSB) autoantibodies. Data extraction and management were performed independently by 2 reviewers (L Zhang and P Zhou). Any disagreement was resolved by discussion or by input from the third reviewer (H Hua). Study quality and bias were assessed using the Newcastle-Ottawa Scale (NOS) criteria, from the following perspectives: (i) the selection of the study groups (4 scores); (ii) the comparability of the groups (2 scores); and (iii) the ascertainment of the exposure and outcome of interest (3 scores). 25 The detailed definition of the assessment is shown in Table S1 . A study would be graded as low, moderate or high quality according to scores of 0-3, 4-6 and 7-9, respectively. 26 Two reviewers (L Zhang and P Zhou) independently assessed the quality of the eligible studies. Disagreement was resolved by discussion or by input from the third reviewer (H Hua).
| Statistical analysis
Statistical analysis was conducted using Stata software (ver. 14.0; Stata Corp., College Station, TX, USA). The data (sample size, mean AE SD) were evaluated with respect to changes of IL-17 levels in patients with pSS vs controls. For certain articles presenting only graphical results, GetData Graph Digitizer software (GetData Pty Ltd., Kogarah, NSW, Australia) was used to convert the graphs into numerical data. Among the studies providing data as median AE interquartile range (IQR) or median AE range, we estimated the mean AE SD following a standard method. 27 The expression of IL-17 in serum, saliva, tear and salivary to evaluate the heterogeneity of the studies, which ranged from 0% to 100%; 25% and 50% were used as cut-offs for modest and high heterogeneity, respectively. 28 If no significant heterogeneity was detected, a fixed-effect model would be used to calculate the pooled effect size. Otherwise, a random effect model would be used. The published Pearson correlation coefficients (r) of IL-17 and clinical or serological markers were also summarized.
Fisher transformation was used to convert each correlation coefficient into an approximately normal distribution, and then the estimate and its 95% CI were transformed back to the original scale. The publication bias was assessed by funnel plot. The SMD and standard error were used as the x-and y-axes of the funnel plot, respectively. Egger's regression was used to detect plot asymmetry. If asymmetry is indicated, the "trim and fill" method would be used to adjust summary estimates for the underlying bias. The basic idea of the trim and fill method is to add studies to the funnel plot until it becomes symmetric. This method trims small studies and fills hypothetical studies until funnel plot symmetry is achieved, can also estimate the number and outcomes of missing studies and then recalculate the revised pooled effect size using original and filled studies. 29 For continuous data, SMD and its variance are recommended as variables for the trim and fill method. The filled funnel plots, with SMD and its standard error as the axes, would be output. Thus, we could evaluate the bias caused by missing articles and estimate the validity and generalizability of the meta-analysis by comparing the original and revised effect sizes.
3 | RESULTS
| Characteristics of the included studies
Based on the search strategy, 1699 studies are retrieved from the relevant databases, and 1611 are excluded after our primary screening due to duplication or not meeting the inclusion criteria. In addition, we record all reasons for study exclusion, disagreements between the 2 reviewers and third reviewer comments. Finally, 45 articles covering 65 studies 18, 20, are included in the meta-analysis, with 31 articles including non-sicca controls, 4 including non-SS controls and 9 including both types of controls. The other included study compares IL-17 expression between patients with pSS with weak or strong lymphocytic infiltration, although no control is involved. In total, 1716 patients with pSS, 892 non-sicca cases and 309 non-SS cases are included in the meta-analysis. In addition, 23 articles covering 32 studies include patients that have not taken steroids or immunosuppressants for at least 3 months before sample collection, 6 articles include a mix of patients with and without immunosuppressive treatment, and 16 articles lack a description of treatment history. Therefore, IL-17 levels are also compared between patients with pSS without immunosuppressive treatment and controls. For the risk of bias assessment, 35 articles are considered high quality (NOS score, 7-9) and 10 are considered moderate quality (4-6), thus indicating that most studies have low risk of bias. The flow diagram for article selection is shown in Figure 1 , and the baseline characteristics of the included articles are summarized in Table 1 .
Of the 45 articles included in the meta-analysis, IL-17 expression (mean AE SD) could be extracted directly from 31 articles, whereas GetData Graph Digitizer is used to digitize the graphical data from the other 14 articles. Pooled data from the studies show that the level of IL-17 in patients with pSS is elevated compared to that in controls (including non-sicca and non-SS controls), although significant heterogeneity is found (SMD, 1.74, 95% CI: 1.38~2.10; I 2 , 94.6%; data not shown). Furthermore, the pooled effect size of the 32 studies including patients not taking immunosuppressants shows a much higher level of IL-17 expression (SMD, 2.52, 95% CI: 1.98~3.06; I 2 , 94.6%; data not shown). A stratified analysis is then conducted to assess the alteration of IL-17 expression in patients with pSS compared to the different control groups.
| Comparison of IL-17 expression between patients with pSS and non-sicca controls
In the meta-analysis, 40 articles covering 49 studies report the expression of IL-17 in patients with pSS and non-sicca controls, including 35 studies report the expression of IL-17 in serum, 6 report IL-17 levels in tears, 4 report IL-17 levels in saliva, and 4 report IL-17 levels in the salivary glands. Among the 35 studies reporting IL-17 in serum, flow cytometry is used in 9 studies, enzyme-linked immunosorbent assays (ELISA) in 18, multiplex bead assays in 7 and polymerase chain reaction (PCR) in 1 study. The expression of IL-17 in the serum of patients with pSS is significantly increased regardless of the detection method used ( Figure 2A ). However, although the overall result from the tear assessment shows higher expression of IL-17 in patients with pSS, a significant difference is only achieved in studies that utilize ELISA for measurement ( Figure 2B ). The pooled effect size from the 4 studies measuring IL-17 in salivary glands by PCR reveals that patients with pSS overexpress IL-17 ( Figure 2C ). For the saliva assessment, a significant increase in IL-17 in patients with pSS is found from the overall result, but the studies using multiplex bead assays show no statistical significance between 2 groups ( Figure S1A ). Among the 49 studies, 24 studies from 22 articles include patients with pSS who have either never received steroids or immunosuppressants or have not received these drugs for at least 3 months before enrolment. Of these studies, 7 use flow cytometry, 8 use ELISA, 4 use 
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| Comparison of IL-17 expression between patients with pSS and non-SS controls
In total, 13 articles covering 14 studies report the expression of IL-17 in patients with pSS and non-SS controls, including 1 study that reports the expression of IL-17 in serum, 6 that report it in tears, 3 in saliva and 4 in the salivary glands. Pooled analysis of IL-17 expression in pSS serum is unavailable due to the limited number of studies. Three of the studies in tears use ELISA, 2 use multiplex bead assays, and 1 uses PCR. The overall result shows overexpression of IL-17 in tears from patients with pSS, although significant difference is only found among studies using ELISA ( Figure 4A ). A significant difference is also found in studies conducted in salivary glands ( Figure 4B ). However, no significant difference is found among studies measuring IL-17 in the saliva of patients with pSS ( Figure S1B ). Similarly, 7 articles covering 8 studies include patients with pSS without immunosuppressive therapy. Two of these studies use ELISA, 4 use multiplex bead assays, and 2 use PCR. Compared with non-SS controls, a significant increase in IL-17 in patients with pSS without immunotherapy is found from the overall result ( Figure 5 ). Moreover, among the 8 studies, 5 studies report the IL-17 expression in tear, 1 study reports the IL-17 expression in salivary gland, and 2 studies report the IL-17 expression in saliva. The pooled effect size from each subgroup also shows the high level of IL-17 in patients with pSS without immunosuppressive treatment ( Figure S3 ).
| Correlation of IL-17 and disease severity
In addition to evaluating alterations of IL-17 in patients with pSS, we explore the correlation between IL-17 levels and disease severity in patients with pSS. Controls are not essential for the analysis. Unfortunately, no study reports the correlation between IL-17 levels and salivary secretion or pSS prognostic factors. In total, 12 studies are included to assess the correlation of histological, serological and ocular severity with IL-17.
| Lymphocytic infiltration
Seven studies report IL-17 levels in patients with pSS with weak or strong lymphocytic infiltration. Four studies measure the IL-17 level in serum, 2 studies measure the IL-17
expression levels between patients with pSS without immunosuppressive therapy and non-sicca controls. The samples from different bodily fluids or salivary gland are mixed, * means samples are from serum, # means samples are from tear, ‡ means samples are from salivary gland, and †means samples are from saliva level in salivary gland, and the other 1 study measures the IL-17 level in saliva; meanwhile, 3 studies use multiplex bead assays to measure the expression of IL-17, 2 use ELISA, and 2 use PCR. However, neither the subgroup results nor the overall result shows the significant difference of IL-17 among patients with different infiltration severity ( Figure 6A ).
| Serological parameters
Two studies evaluate the difference in IL-17 expression in serum between patients with pSS that are positive and negative for anti-Ro/SSA and anti-La/SSB antibodies; the results reveal no statistically significant difference between these 2 patient groups ( Figure S4 ). In contrast, rheumatoid factor (RF)-positive patients tend to show higher IL-17 expression compared to negative RF patients with pSS ( Figure 6B ).
| Ocular parameters
Three studies report the correlation between IL-17 expression levels in tear and tear film break-up time (TBUT), as well as the Schirmer I test. Pooled data show a negative 
| Publication bias
The asymmetry of the funnel plot and the results of Egger's regression (P < .01) both indicate the presence of publication bias. Therefore, the "trim and fill" method is used to adjust for bias. Compared to the previous pooled effect size (SMD, 1.74, 95% CI: 1.38~2.10), the pooled SMD after adjustment (SMD, 0.67, 95% CI: 0.10~1.25) still remains significant, although the increased level of IL-17 expression is reduced. This suggests that the results of the meta-analysis are still valid, although publication bias must nevertheless be considered (Figure 7 ).
| DISCUSSION
Sj€ ogren's syndrome is a complex and multifactorial autoimmune disease, the pathogenesis of which still remains unclear. The most accepted aetiology of SS relates to aberrant inflammation, which leads to destruction of the epithelium in the exocrine glands and lymphocytic infiltration. 73 The impact of abnormal cytokine production in SS has attracted considerable attention. 74 As an important proinflammatory cytokine, IL-17 is related to a wide range of pathological inflammatory conditions, including autoimmune diseases, metabolic disorders and cancers. 15 In autoimmune disorders, IL-17 can promote the expression of chemokines, which drive recruitment of inflammatory cells, including monocytes, neutrophils, dendritic cells and Th17 cells. 75 Meanwhile, IL-17 can increase the expression of various pro-inflammatory cytokines, which may in turn aggravate inflammation and cause organ destruction. 75 In addition, IL-17 could stimulate the release of matrix metalloproteinases, destroying components of the extracellular matrix and resulting in compromised function of the exocrine glands. 76, 77 In recent years, several articles have explored the aberrant expression of IL-17 in patients with pSS. The aim of this comprehensive meta-analysis is to clarify alterations of IL-17 in the serum, tears, saliva and salivary glands of patients with pSS, as well as its correlation with disease severity. Non-sicca controls and non-SS controls are both included in the meta-analysis. In contrast to the non-sicca controls, lymphocytic infiltration could occur in the exocrine glands of non-SS controls. 32 Furthermore, cytokine expression and release could also be aberrant in non-SS controls. 37 Therefore, it is essential and meaningful to include the 2 different controls simultaneously. When compared with non-sicca controls, a significant increase in IL-17 is found in the serum, tears, saliva and salivary glands of patients with pSS, with the largest difference in IL-17 levels seen in tears. Similarly, a significant difference is found in IL-17 levels in the tears and salivary glands of patients with pSS compared with non-SS controls. These data indicate the important role of IL-17 in the pathogenesis of pSS. Among the autoimmune disorders, SS remains one of the most difficult to manage. The treatment of pSS is based on symptomatic management of sicca manifestations and the use of immunosuppressive agents for systemic disease. 3 We evaluate 23 articles that include patients without systemic treatment to exclude the influence of immunosuppressants. The results further confirm the elevated expression of IL-17 in patients with pSS. Compared with the pooled effect size derived from all 45 articles, alterations of IL-17 in patients without immunosuppressive treatment seem to be greater, which indicate a possible effect of immunosuppressants on alleviating inflammation.
Lymphocytic infiltration in exocrine glands is the most important histological characteristic of patients with pSS. Previous studies have shown that IL-17 is mainly expressed in the periductal and perivascular infiltrates of the salivary glands, 20, 43, 78 with the level of expression correlated with the severity of glandular inflammation. 79 However, among the 7 studies reporting IL-17 expression under conditions of weak and strong lymphocytic infiltration, no significant overexpression of IL-17 in severe inflammatory patients is found. Notably, no consistent cut-off value is used for distinguishing weak from strong infiltration among the 7 studies. Four studies evaluate inflammation using Greenspan's focus score 80 ; a score of 6 is used as a cut-off value for distinguishing weak and strong infiltration. Three articles use the AECG classification criteria for pSS (focus score ≥1 foci/4 mm 2 for the minor salivary gland); 2 of these studies use a focus score of 1 as a cut-off for weak and
Funnel plot of studies adjusted by trim and fill method strong infiltration, and the other study defines weak infiltration as 1-2 foci per lobule of labial salivary glands. This inconsistency may be attributable to the high heterogeneity among the included studies, which could bias the pooled effect size. This must be kept in mind when interpreting the results. In addition, our results indicate that there is no difference in IL-17 expression between patients who are positive and negative for anti-Ro/SSA and anti-La/SSB antibodies. Similar results have been reported previously. 50 Ro/SSA and La/SSB are extractable nuclear antigens, while anti-Ro/ SSA and anti-La/SSB antibodies are among the most common autoantibodies found in patients with pSS, being present in 50%-70% of patients. 81 Previous studies have suggested that anti-Ro/SSA and anti-La/SSB antibodies are associated with a longer disease duration, more severe dysfunction of the exocrine glands and stronger lymphocytic infiltration in the salivary glands. 81 However, this analysis, as along with other previous reports, fails to find a correlation between IL-17 levels and those of the 2 antibodies. Surprisingly, RF, an important serological marker of pSS, is significantly related to elevated expression of IL-17 in patients. Furthermore, a previous study also found that RF levels were positively correlated with IL-17 expression. 50 These results indicate that, to some extent, IL-17 combined with certain serological parameters has some utility in the evaluation of disease severity in patients with pSS. The salivary flow rate, TBUT and Schirmer I test are important for evaluating the severity of dryness. However, few studies explore the correlation between IL-17 levels and the salivary flow rate. Regarding the ocular parameters, the TBUT and Schirmer I test are negatively correlated with tear IL-17 levels in patients with pSS. These ocular parameters could constitute an important reference for clinicians to determine the severity of pSS and develop treatment plans. These results reveal a possible correlation between IL-17 and dry eye symptoms in patients with pSS. However, considering the small number of studies involved, additional studies are still needed to confirm the results.
Although the SS Foundation has developed clinical practice guidelines for the management of the oral, ocular and rheumatologic or systemic manifestations of patients with pSS in 2016, no curative therapy for SS exists. 82 Given the need for treatments for these patients, cytokine imbalances and the proven physiopathological mechanisms offer therapeutic opportunities. 83 Biological treatment has attracted significant attention recently. B cell depletion therapy with rituximab has shown beneficial effects on glandular morphology, dryness and several extraglandular manifestations in patients with pSS. 84 Regarding IL-17, monoclonal antibodies targeting IL-17 or the IL-17 receptor have proven effective in alleviating the course of psoriasis, inflammatory bowel disease and arthritis, but have not yet been applied in patients with pSS. 3 The evidence provided by this meta-analysis suggests that IL-17 is aberrantly expressed in pSS and correlated with disease severity, which could provide a theoretical basis for the development and application of therapies targeting IL-17 for the treatment of pSS. Lymphoma is a leading cause of mortality in patients with pSS. 85 Reported predictors of lymphoma include lymphadenopathy, parotid enlargement, palpable purpura, low C4 serum levels and cryoglobulins. 86 Although no study specifically evaluated the correlation between IL-17 and the development of lymphoma in pSS, a relationship between IL-17 and lymphoproliferative disease has been posited. Circulating IL-17 levels are significantly increased in patients with anaplastic large cell lymphoma and acute lymphoblastic leukaemia. 87, 88 In addition, relatively lower serum IL-17 expression is a positive predictor of 3-year progression-free survival for patients with extranodal natural killer/T cell lymphoma. 89 Moreover, IL-17 may be prognostic factor for B lymphoma by inducing radiation resistance. IL-17 could suppress p53 expression and thereby repress irradiation-triggered apoptosis of lymphoma cells. 90 Therefore, we speculate that IL-17 is a key prognostic factor for lymphoma. Further studies are still needed to reveal the risk conferred by IL-17 overexpression with respect to the onset of lymphoma in patients with pSS. Overall, there are several limitations to our analysis, necessitating significant caution when interpreting the results. The main limitation is the high heterogeneity of some estimates. It is difficult to elucidate the source of the heterogeneity, but we assume that diversity in the study designs, sample sizes, disease durations and measurement errors all contribute. Second, the number of included articles and the overall sample size are small in the contest of assessing the significance of IL-17 for disease severity. Even though a negative correlation is found between IL-17 levels and ocular parameters, the available evidence is still not sufficient to draw a firm conclusion. Third, the underlying publication bias must be considered. Although our literature search is as comprehensive as possible, Egger's regression still shows the presence of small-study effects. However, overexpression of IL-17 is still determined in the patients with pSS, although the adjusted result shows that the increase in IL-17 levels is somewhat reduced. The results indicate that studies with a small sample size or negative findings may not always be published. All of these limitations should be borne in mind when interpreting the results.
In conclusion, by analysing the data of studies that have investigated IL-17 levels in patients with pSS, especially in those not receiving immunosuppressive therapies, this meta-analysis provides robust evidence that IL-17 is increased in patients with pSS. Certain parameters that are important in pSS, such as RF and ocular signs, are found to be correlated with the expression level of IL-17. These findings suggest that IL-17 may participate in the onset and progression of pSS and may provide evidence that could inform the development of therapeutic approaches for pSS targeting IL-17.
